Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Titan’s Probuphine May Be Limited By Implant Procedure

Executive Summary

Extensive requirements for training and equipping non-surgical specialists to implant the product for opioid dependence treatment may scare some clinicians away from using it, advisory committee members say.

You may also be interested in...



PDUFA VII: US FDA Wants Dedicated RMAT Program Funding

Cell and gene therapy product activities also have increased CBER’s workload significantly and strained staff, the agency tells industry representatives.

An Orange Book By Any Other Name …

One of US FDA’s most important publications ever, the Orange Book celebrates 40 years as the definitive guide to approved drug products and therapeutic equivalents. Even as the color has receded from the book itself, orange still generates appreciation from regulators and outside attorneys.

Patient Warehousing Emerges As Another COVID-19 Vaccine Confidence Problem

CDC officials designing distribution plans worry some eligible for vaccination may wait for a better product to emerge.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel